scripod.com
20VC: Inside Carnegie Mellon's $4BN Endowment | Why 90% of LPs Shouldn't Invest in VC | The $140BN Problem with Multi-Stage Funds | The Hidden Math Behind DPI, TVPI, and Illiquidity with Miles Dieffenbach

Overview

Shownote

Highlights

Transcript

Chapters

Pins

20VC: Inside Carnegie Mellon's $4BN Endowment | Why 90% of LPs Shouldn't Invest in VC | The $140BN Problem with Multi-Stage Funds | The Hidden Math Behind DPI, TVPI, and Illiquidity with Miles Dieffenbach

The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

2025/08/04
The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

2025/08/04
OverviewShownoteHighlightsTranscriptChaptersPins

Shownote

Miles Dieffenbach is Managing Director of Investments at Carnegie Mellon University, where he helps oversee a $4 billion endowment with a focus on venture capital, private equity, and alternative investments. Under his leadership, CMU's private book has re...

Highlights

In this insightful conversation, Miles Dieffenbach, Managing Director of Investments at Carnegie Mellon University, shares his personal journey through cancer and how it shaped his resilient mindset. Transitioning into his professional expertise, he provides a deep dive into managing a $4 billion endowment, shedding light on the complexities of venture capital, private equity, and alternative investments. The discussion also explores broader themes in the venture capital ecosystem, including performance challenges, access issues, and evolving market dynamics.
05:45
Decided to face cancer actively after diagnosis, leading to recovery in four months
07:02
Private equity has been self-funding for three years and is the main distribution contributor
10:46
Venture capital is considered the riskiest private asset class.
13:31
New allocators are unlikely to access top-decile managers.
16:01
Union Square is noted for its strength in selling within venture capital.
22:29
Premier funds have strong networks while esoteric strategies target niche markets
24:02
Sourcing in venture capital is a young person's game and involves a lot of luck and hustle.
31:52
GPs should aim for a diversified LP base with no single investor exceeding 10% concentration
34:31
Selling part of the management company is a red flag in fundraising
40:51
Index praised for performance-driven culture and restraint in fund-raising.
58:32
A 13-year fund benefited significantly from Circle's growth into a $50B company after being undervalued.

Chapters

I Had Cancer at 26 – It Changed Everything
00:00
Inside the $4BN Carnegie Mellon Endowment: The Investment Blueprint
07:00
Are LPs Getting Screwed in Venture?
10:45
90% of LPs Shouldn’t Be in Venture – Here’s Why
13:30
Seed Funds Are a Trap (And No One Wants to Admit It)
16:00
The $140BN Problem with Multi-Stage Funds
20:00
Index Is the Best in the Game – Here's Why They Win
24:00
The Dirty Secret of LPs: Brand Over Performance
29:30
When Founder-Friendly Goes Too Far
34:30
The OpenAI Bubble – Will It All Go to Zero?
38:00
Ping Pong Diligence & Wildest Fundraising Stories
44:00

Transcript

Miles Dieffenbach: So my message here to all venture capitalists, now is the time. Please take your companies public. I breathe investing. These business models these GPs are creating are some of the best high margin businesses ever created. My question to...